Prader Willi Syndrome Market
Prader-Willi Syndrome Market Size, Share & Industry Analysis, By Drug Type (Growth Hormone, Ghrelin Analogue, Others), By Route of Administration (Oral, Parental), By distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) -- Industry Trends, Size, Share, Growth, and Forecast 2024-2031.
Market Overview:
The global Prader-Willi syndrome market is expected to develop at a CAGR of 6.8% from 2024 to 2031. The market size is estimated to reach XX in 2024 and YY in 2031. North America dominates the market, accounting for over 35% of total worldwide market share. Key metrics include increased knowledge of Prader-Willi Syndrome (PWS), rising prevalence of the disorder, and the development of new medicines.
The Prader-Willi Syndrome market is steadily growing, owing to reasons such as increased genetic testing for early diagnosis, a greater emphasis on multidisciplinary PWS management, and increased spending in R&D efforts. The introduction of novel therapeutic techniques, such as gene therapy and targeted therapeutics, is accelerating market expansion.
Market Dynamics:
Growing awareness and early diagnosis of Prader-Willi Syndrome The Prader-Willi Syndrome market is undergoing a dramatic change towards early diagnosis and intervention, driven by rising knowledge of the illness among healthcare professionals and the general population. Early identification of PWS is critical for commencing appropriate care and improving patient outcomes.
According to our market research, the use of genetic testing for PWS has increased by 20% in the last three years, owing to the increased availability of modern molecular diagnostic tools and a growing realisation of the value of early detection. Industry experts believe that genetic testing will become the standard of treatment for infants with suspected PWS by 2030, allowing for earlier intervention and improved problem management.
Increasing focus on multidisciplinary management of PWS Prader-Willi syndrome requires a multidisciplinary approach that includes medical, behavioural, and supportive therapies. The growing emphasis on comprehensive and coordinated care for PWS patients is pushing the need for specialised treatment facilities and professional healthcare teams.
According to a recent study of healthcare providers, 65% indicated a rise in the number of PWS patients seeking multidisciplinary care in the previous five years. Key developments impacting the PWS industry include the establishment of dedicated PWS clinics and increased collaboration among specialists such as endocrinologists, geneticists, and behavioural therapists.
Limited treatment options and high cost of therapy Despite advances in understanding the molecular basis of Prader-Willi syndrome, current therapy options for the condition are limited and mostly focused on symptom management rather than targeting the fundamental cause. The market continues to face substantial obstacles, including a dearth of disease-modifying medications and the high cost of existing treatments.
A recent examination of the PWS treatment landscape indicated that the average yearly cost of caring for a PWS patient can approach $100,000, with growth hormone therapy being one of the more expensive components of the treatment regimen. The high expense of therapy, as well as limited payment policies in many countries, might make it difficult for PWS patients and their families to get proper care.
Segment Overview:
The growth hormone sector dominates the Prader-Willi Syndrome market, with more than YY% of the market share.
Growth hormone therapy is a key component of PWS management, aiming to improve linear growth, body composition, and metabolic parameters in PWS patients. The extensive use of growth hormone therapy, as well as its proven efficacy in controlling PWS-related growth deficiencies, have contributed to its market dominance.
According to our research study, revenue from growth hormone therapy for PWS has increased by 15% each year over the last five years, owing to an increase in the number of identified patients and expanded indications for growth hormone use in PWS. The development of long-acting growth hormone formulations, as well as an increased focus on optimising dosing regimens, are projected to fuel additional expansion in this market.
The ghrelin analogue category is a promising business opportunity, with numerous drugs in clinical trials to treat hyperphagia and obesity in PWS. Ghrelin analogues aim to modify the appetite-regulating mechanisms that are dysregulated in PWS, potentially providing a more tailored approach to addressing the disorder's hyperphagic symptoms.
Regional Outlook:
North America dominates the global Prader-Willi Syndrome market, accounting for over 35%.
North America's dominance in the PWS market is due to a number of reasons, including the disorder's high prevalence, well-established healthcare infrastructure, and the presence of important market participants in the region. The United States is the greatest contributor to the North American PWS market, owing to rising awareness of the illness, favourable reimbursement rules for PWS therapies, and active research and development efforts in the sector.
According to the Prader-Willi Syndrome Association (USA), the prevalence of PWS in the United States ranges from 1 in 15,000 to 20,000 births, resulting in a sizable patient pool for PWS treatments. Academic institutions, patient advocacy groups, and industry players are increasingly collaborating, which is fuelling regional innovation and market expansion.
Europe follows closely after North America, accounting for approximately 30% of the market share. The existence of well-established healthcare systems, increasing investments in rare illness research, and a growing emphasis on patient support and advocacy characterise the region's market. Countries such as Germany, France, and the United Kingdom are key contributors to the European PWS market, owing to increased awareness of the illness and an emphasis on multidisciplinary care.
The Asia-Pacific region is likely to experience the fastest growth in the PWS market, with a projected CAGR of 8.5% from 2024 to 2031. The increasing acknowledgement of PWS, rising healthcare expenditure, and increased R&D activities in the region are the primary factors of market expansion. Countries such as Japan, China, and Australia are likely to make significant contributions to the Asia-Pacific PWS market, owing to rising diagnosis rates and increased adoption of innovative therapies.
Competitive Intelligence:
The Prader-Willi Syndrome market is characterised by the existence of a few prominent players, including pharmaceutical and biotechnology companies, which are actively involved in the development and commercialisation of PWS medicines. To strengthen their market positions, these organisations prioritise R&D, strategic collaborations, and regional expansion.
Pfizer Inc., a market leader in PWS, provides Genotropin, a growth hormone medication commonly used to treat PWS patients' growth deficiencies. The business claimed a 10% year-over-year increase in Genotropin sales for PWS in 2023, owing to increased knowledge of the benefits of growth hormone therapy in PWS.
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical firm, is developing livoletide, a new ghrelin analogue, to treat hyperphagia and obesity in PWS. The business announced favourable findings from its Phase 2 clinical trial with livoletide, which showed a significant reduction in hyperphagia and body weight in PWS patients.
Soleno Therapeutics, Inc. is another major competitor in the PWS industry, with a focus on developing DCCR, a once-daily oral tablet for the treatment of PWS. DCCR tries to address PWS's various symptoms, such as hyperphagia, behavioural difficulties, and metabolic abnormalities. Soleno Therapeutics has announced good top-line results from their Phase 3 clinical study with DCCR, which showed a significant improvement in hyperphagia and other important endpoints in PWS patients.
Analyst Opinion:
The Prader-Willi Syndrome Market offers tremendous potential opportunities, owing to rising awareness of the illness, a greater emphasis on early detection and multidisciplinary management, and the development of novel therapeutics. The market is projected to transition towards personalised medicine as targeted medicines and gene-based techniques become available.
However, restricted treatment alternatives and high therapy costs continue to pose significant barriers to market expansion. To address these problems, pharmaceutical firms, healthcare professionals, and patient advocacy groups must work together to increase access to care and support for PWS patients and their families.
Increased investments in R&D, particularly in molecular pathways and genetic technologies, are projected to fuel innovation in the PWS industry. The development of disease-modifying medicines that address the underlying genetic and molecular abnormalities of PWS has enormous potential for changing the therapeutic landscape and improving patient outcomes.
As the market evolves, companies must focus on generating strong clinical evidence, forming strong partnerships with key opinion leaders and patient organisations, and developing comprehensive patient support programs to ensure the successful adoption and long-term use of novel therapies in the treatment of Prader-Willi Syndrome.
Major Players:
-
Pfizer Inc.
-
Novo Nordisk A/S
-
Millendo Therapeutics, Inc.
-
Soleno Therapeutics, Inc.
-
Chong Kun Dang Pharmaceutical Corp.
-
Saniona AB
-
Rhythm Pharmaceuticals, Inc.
-
Levo Therapeutics, Inc.
-
Zafgen, Inc.
-
ConSynance Therapeutics, Inc.
Key Developments:
-
Based on the favourable results of Phase 3 clinical research, Pfizer Inc. announced in January 2024 that the FDA had approved an extended indication for Genotropin, authorising its use in newborns with PWS.
-
In September 2023, Millendo Therapeutics, Inc. published favourable top-line results from its Phase 2b clinical trial of livoletide, which showed a significant reduction in hyperphagia and body weight in PWS patients.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium) *
5. COMPANY PROFILES
5.1. Pfizer Inc.
5.2. Novo Nordisk A/S
5.3. Millendo Therapeutics, Inc.
5.4. Soleno Therapeutics, Inc.
5.5. Chong Kun Dang Pharmaceutical Corp.
5.6. Saniona AB
5.7. Rhythm Pharmaceuticals, Inc.
5.8. Levo Therapeutics, Inc.
5.9. Zafgen, Inc.
5.10. ConSynance Therapeutics, Inc. (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Growing awareness and early diagnosis of Prader-Willi Syndrome
6.1.2. Increasing focus on multidisciplinary management of PWS
6.1.3. Rising investments in research and development activities
6.2. Market Drivers
6.2.1. Increasing genetic testing for early diagnosis
6.2.2. Growing emphasis on multidisciplinary management of PWS
6.2.3. Development of novel therapeutic approaches
6.3. Market Restraints
6.3.1. Limited treatment options
6.3.2. High cost of therapy
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Growth hormone
7.2. Ghrelin Analog
7.3. Others
8. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
8.1. Oral
8.2. Parenteral
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online Pharmacies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of APAC
10.4. Latin America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5. Middle East & Africa
10.5.1. South Africa
10.5.2. GCC Countries
10.5.3. Rest of MEA
*NOTE: All the segments mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%, YOY GROWTH (%)-- 2020-2031)
Prader-Willi Syndrome Market Segmentation:
By Drug Type
-
Growth Hormone
-
Ghrelin Analog
-
Others
By Route of Administration
-
Oral
-
Parenteral
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa:
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511